The split is no surprise: it has been public knowledge since the end of 2018 that GSK is going to spin off its consumer health business into a joint venture with Pfizer, but this is the first time ...

GlaxoSmithKline’s chairman, Philip Hampton, may be considering splitting the company amid pressure from top investors to separate the company into consumer, pharma and vaccines divisions.

Activist investor Elliot Advisors has bought a multibillion pound stake in the company and has been trying to convince others that GSK would be better off - and worth more - if it were split up ...